Company “Panacela Labs” LLC (Russia) is open to any interaction forms with investors and development institutes. Panacela Labs is the owner of all intellectual property of product Mobilan, territorial protection includes Russia and CIS countries, Europe, USA, Japan and Canada. Product Mobilan by Panacela Labs is on the stage of clinical studies so preclinical risks are absent in the project, hereby the drug mode of action allows to use it not only for therapy of prostate cancer but also treatment for other cancer diseases which are characterized by availability of primary tumor for injection.
To know more about Mobilan studies:
https://clinicaltrials.gov/ct2/show/NCT02844699?term=M-VM3&rank=2